A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
复制标题
DOI：
10.1038/s41541-020-0185-6
复制
发表时间：
2020-05-15
期刊：
影响因子：
9.2
通讯作者：
Hoffmann, Donata
中科院分区：
文献类型：
--
作者：
Schoen, Jacob;Ran, Wei;Hoffmann, Donata
H5亚型高致病性禽流感病毒（hpaiv）是全世界家禽饲养的主要威胁，特别是人畜共患的亚洲H5N1病毒。这些高致病性禽流感病毒已造成500多例从家禽到人类的致命外溢感染，通过建立人与人之间的传播，一种新的大流行的危险正在逼近。除了在流行地区的受感染农场采取扑杀措施外，疫苗接种是对抗HPAIV的主要工具。然而，主要使用的灭活制剂有几个局限性，如通过注射应用于单个动物和效率降低。本文提出了一种基于H17N10蝙蝠流感病毒的改良流感活疫苗原型。新的嵌合疫苗株R65(mono)/H17N10能够在经口鼻免疫后对雏鸡和亚成年鸡以及雪貂的HPAIV H5N1致命攻击感染提供充分保护。此外，H5疫苗原型不能与禽流感病毒重新组合，因此是对抗HPAIV H5感染的有希望的工具，允许有效控制疾病的新疫苗接种策略。
Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by establishing human-to-human transmissions. Besides culling measures in infected farms in endemic areas, vaccination is the major tool against HPAIV. However, the mainly used inactivated preparations have several limitations, like application to the individual animal by injection and a reduced efficiency. Here we present a modified live influenza vaccine prototype, which is based on the H17N10 bat influenza virus. The new chimeric vaccine strain R65(mono)/H17N10 was able to provide full protection against a lethal challenge infection with HPAIV H5N1 of juvenile and subadult chickens, as well as ferrets after oronasal immunization. In addition, the H5 vaccine prototype cannot reassort with avian influenza viruses and therefore is a promising tool against HPAIV H5 infection, allowing new vaccination strategies for efficient disease control.